Exploiting a novel organotypic model of SOX2-driven early squamous lung cancer to identify potential routes to chemoprevention

Lung cancer is a devastating disease and is the leading cause of cancer related death globally. Squamous cell lung cancer (SQC) accounts for around 25% of all lung cancer diagnoses. Better strategies for the early detection, prevention and treatment of lung cancer are urgently needed. Using a novel in vitro model of SOX2-driven early SQC I performed a screen using tool compounds and compounds in late phase clinical development for potential efficacy in chemoprevention. I combined this approach with targeted genetic ablation studies to identify/characterise targets that may be key to the progression of SOX2-driven squamous cell carcinomas. In particular I highlight an AKT isoform dependence in SQC that could be exploited in future clinical chemoprevention studies.

Name dc:type.qualificationname

Doctor of Philosophy (PhD)

Level dc:type.qualificationlevel

Doctoral

Grantor dc:publisher.institution

University of Cambridge

Year dc:date.issued

2020

Author dc:creator

• Barry, Philip Simon

Advisor dc:contributor.advisor

• McCaughan, Frank

• lung cancer
• SOX2
• squamous
• AKT3
• chemoprevention
• squamous cell lung cancer

Licence

• https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/37f28e44-d168-44aa-9a53-4a4910e98842/download
• https://creativecommons.org/licenses/by-nc-nd/4.0/

Language dc:language

en

Author Identifier

0000-0001-6031-6347

OAI identifier oai:identifier

oai:www.repository.cam.ac.uk:1810/303261